Abstract. Cervical cancer is one of the primary causes of cancer-associated mortality worldwide. Due to the increasing incidence of cervical cancer, multiple treatment options are required. Initial responses to chemotherapy and surgical interventions are generally positive, however patients often experience relapse and tumor recurrence. Currently, the effects of cucurbitacins on different types of cancer are being investigated, as they exhibit a wide variety of bioactivities. The anticancer activity of the cucurbitacin 23,24-dihydrocucurbitacin B against a panel of human cervical cancer cell lines was investigated in the current study. Cell viability was determined using an MTT assay and apoptosis was detected using DAPI staining. The proportion of apoptotic cells, cell cycle distribution, mitochondrial membrane potential (ΔΨ m ) and reactive oxygen species (ROS) levels were estimated using flow cytometry. Protein expression was determined using western blot analysis. The results of the current study indicated that 23,24-dihydrocucurbitacin B inhibited the viability of human cervical cancer cell lines and had an IC 50 of 40-60 µM. However, its cytotoxic effects were much less pronounced in normal epithelial fr2 and HerEpiC cells, where it had an IC 50 of 125 µM. The underlying mechanisms of this were further studied and the results demonstrated that 23,24-dihydrocucurbitacin B induced apoptosis in HeLa cells and caused ROS-mediated shifts in the ΔΨ m . Additionally, it caused the cell cycle arrest of HeLa cells at the G 2 /M checkpoint. The phosphoinositide 3 kinase/protein kinase B/mechanistic target of rampamycin (PI3K/AKT/mTOR) cascade may serve an important role in cancer tumorigenesis, progression and resistance to chemotherapy. The results indicated that 23,24-dihydrocucurbitacin B significantly decreased the expression of important proteins in the PI3K/Akt/mTOR cascade. Taken together, these results suggest that 23,24-dihydrocucurbitacin B may be novel method of treating cervical cancer.
Introduction
Cucurbitacins are secondary plant metabolites chemically categorized as steroids. They are synthesized by a range of plant species, particularly by those that are part of the cucurbitaceae family (1) . Cucurbitacins normally exist as glycosides and help plants to deter predators (1) . It has been reported that cucurbitacins exhibit anticancer activities against different types of cancer (2) (3) (4) ; however, the antitumor activity of 23,24-cucurbitacin B against cervical cancer cells remains unclear. Therefore, the present study aimed to investigate the anticancer effects of 23,24-dihydrocucurbitacin B against the human HeLa cervical cancer cell line. Cervical cancer is the third most commonly diagnosed cancer in females worldwide. Every year, >500,000 females are diagnosed with cervical cancer, which accounts for ~9% of all newly diagnosed cancer cases globally (5) . Existing treatments, including radical hysterectomy and radiotherapy, have outcomes; however, cervical cancer continues to account for ~300,000 mortalities every year (5) . Surgery is the only appropriate option for early stage cervical cancer and the majority of cervical cancers are diagnosed at advanced stages (5) . Advanced stage cervical cancers are treated with radiotherapy, which induces severe side effects, including skin reactions, hair loss, pain, tiredness and fatigue and lymphodeama, which affect the patient's quality of life (6) .
The present study evaluated the effect of the cucurbitacin 23,24-dihydrocucurbitacin B on human cervical cancer cells. Its underlying mechanism of action was assessed with particular emphasis on the effect of 23,24-dihydrocucurbitacin B on the phosphoinositide 3 kinase/protein kinase B/mechanistic target of rampamycin (PI3K/Akt/mTOR) cascade. The expression of proteins in the PI3K/Akt/mTOR pathway is dysregulated in several types of cancer (7) . The first generation of molecules, including rapamycin and its analogues that inhibit mTOR also exhibit potent anticancer activity against different types of cancer, including pancreatic, cervical, ovarian and breast cancer (7) . Currently, P13K, Akt and the second generation of molecules, including temsirolimus, everolimus, and deforolimus that inhibit mTOR are being investigated in clinical trials (7, 8) . The current study determined the effect of 23,24-dihydrocucurbitacin B on apoptosis, reactive oxygen species (ROS) levels, the mitochondrial membrane potential (ΔΨ m ) and the cell cycle of cells from the human cervical HeLa cancer cell line. Additionally, the effect of 23,24-dihydrocucurbitacin B on the expression of important proteins within the PI3K/Akt/mTOR signaling pathway was evaluated. The aim of the current study was to identify whether 23,24-dihydrocucurbitacin B exhibits significant anticancer activity, in order to determine whether 23,24-dihydrocucurbitacin B may be developed as a novel method of treating cervical cancer.
Materials and methods
Cell culture conditions. The cervical cancer cell lines C33A, ME-180, C4-1 and HeLa, the normal cell line fR2 and human cervical epithelial cells (HCerEpiC) were obtained from the Cancer Research Institute of Beijing (Beijing, China) and maintained in Dulbecco's modified Eagle's medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), 100 µg/ml streptomycin and 100 U/ml penicillin G (HiMedia, West Chester, Pennsylvania, USA) in an incubator at 37˚C with 5% CO 2 .
MTT assay. The medium was removed and 500 µl dimethyl sulfoxide was added to each well to dissolve formazan crystals. Optical density was recorded using an ELISA plate reader at a wavelength of 570 nm. 23,24-dihydrocucurbitacin B exhibited marked anticancer activity against all cell lines; however, further experiments were performed on the HeLa cancer cell line alone as the lowest MIC was observed against this cell line.
Colony formation assay. HeLa cells were cultured to the exponential phase (70% confluence), collected and counted using a hemocytometer. Cells were then seeded at a density of 200 cells/well and incubated for 24 h to allow cells to adhere. Cells were then treated with different concentrations of 23,24-dihydrocucurbitacin B (0, 20, 40 and 80 µM). Cells were incubated for 6 days and then washed with PBS. This was followed by fixation with 70% methanol at -20˚C for 24 h and staining with 0.01% (w/v) crystal violet for 35 min at 25˚C. Cells were then counted in 10 fields using a light microscope at a magnification of x200.
Apoptosis detection. HeLa cells were cultured to a density of 2x10 5 cells/well in 6-well plates and were subsequently treated with 0, 20, 40 and 80 µM 23,24-dihydrocucurbitacin B for 24 h. Cells were then stained with DAPI for 20 min at room temperature. The cells were then fixed with 70% methanol at -20˚C overnight and observed using fluorescence microscopy (magnification, x200). A similar procedure was followed for Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) (Sigma-Aldrich; Merck KGaA) staining; cells were stained with annexin V/PI and investigated using a flow cytometer, (BD Biosciences, San Jose, CA, USA) following the manufacturer's protocol and BD FACSuite software version 1.0 for analysis.
Estimation of ROS and ΔΨ m . HeLa cells were seeded at a density of 2x10
5 cells/well in 6-well plates and incubated for 24 h. Cells were then treated with 0, 20, 40 and 80 µM 23,24-dihydrocucurbitacin B for 24 h at 37˚C in 5% CO 2 . Cells were washed twice with PBS and resuspended in 500 µl dihydrofluorescein diacetate (10 µM) (Sigma-Aldrich; Merck KGaA) for mitochondrial ROS estimation and DiOC 6 (1 µmol/l) at 37˚C in a dark room for 35 min to measure the ΔΨ m . Samples were then investigated using a flow cytometer following a previously described protocol (9, 10) .
Cell cycle distribution of HeLa cells using flow cytometry.
HeLa cells were harvested and washed twice with PBS. Cells were then fixed with 70% ethanol for ~1 h at -20˚C and then washed again with PBS. Cells were resuspended in a solution of PI (50 µl/ml) and RNase1 (250 µg/ml) (Invitrogen; Thermo Fisher Scientific, Inc.). This was followed by incubation for 30 min at room temperature and fluorescence-activated cell sorting using 10,000 cells/group with a flow cytometer.
Western blot analysis.
Following treatment with various concentrations of 23,24-dihydrocucurbitacin B, cells were harvested and lysed in radioimmunoprecipitation lysis buffer (20 mM HEPES, 350 mM NaCl, 20% glycerol, 1% 
Results

Cytotoxic potential of 23, 24-dihydrocucurbitacin B on cervical cancer cells.
The cytotoxic potential of 23,24-dihydrocucurbitacin B (Fig. 1A ) was evaluated against a panel of human cervical cancer cell lines ( (Fig. 1C) . A colony formation assay was performed and the results indicated that following 23,24-dihydrocucurbitacin B administration, the percentage of colonies of HeLa cells decreased in a dose-dependent manner (Fig. 2) . (Fig. 3) . Annexin V-FITC/PI staining and flow cytometry indicated that the percentage of apoptotic cells significantly increased after 24 h incubation with 20, 40 and 80 µM 23,24-dihydrocucurbitacin B, compared with untreated cells (Fig. 4) . Higher concentrations of 23,24-dihydrocucurbitacin B induced a higher rate of apoptosis, indicating that 23,24-dihydrocucurbitacin B induces apoptosis in a concentration-dependent manner. (Fig. 5B) . 
23,24-dihydrocucurbitacin B induces apoptosis in
23,24-dihydrocucurbitacin B causes ROS activation in
23,24-dihydrocucurbitacin B induces cell cycle arrest.
Cell cycle arrest is one of the important mechanisms by which anticancer agents exert their inhibitory effects (12) . Therefore, the effect of 23,24-dihydrocucurbitacin B on the cell cycle of HeLa cancer cells was determined in the present study. The results indicated that the number of HeLa cells was markedly increased in the G 2 phase of the cell cycle at doses of 20-80 µM of 23,24-dihydrocucurbitacin B, thereby inducing G 2 arrest (Fig. 6 ). The proportion of HeLa cells in the G 2 phase were slightly increased at a concentration of 20 µM, moderately increased at 40 µM and highly increased at 80 µM suggesting that 23,24-dihydrocucurbitacin B induces the G 2 /M arrest of HeLa cancer cells in a dose-dependent manner. (Fig. 7) . These decreases occurred in a dose-dependent manner.
23,24-dihydrocucurbitacin B targets the mTOR/PI3K/
Discussion
Cervical cancer is one of the most common types of cancer diagnosed in women worldwide and ~5 Lakh women are diagnosed with the disease annually (5). Existing treatment options, including radical hysterectomy and radiotherapy have good clinical outcomes; however, cervical cancer continues to account for a high number of cancer-associated mortalities. Surgery is the most appropriate treatment option if the cancer is detected at an early stage; other treatment options, such as radiotherapy have severe side effects, including skin reactions, hair loss, pain, tiredness and fatigue and lymphodeama, which adversely affect the patient's quality of life (6) . Thus, the identification of novel treatments for cervical cancer that induce limited side effects is required. In the present study, the anticancer activity of 23,24-dihydrocucurbitacin B was evaluated in a panel of cervical cancer cell lines, including C33A, ME-180, C4-1 and HeLa, and the normal cervical cell lines fR2 and HCerEpiC. 23,24-dihydrocucurbitacin B exhibited anticancer activity against all of the cervical cancer cell lines used. However, the highest activity was observed against HeLa and C4-1 cervical cancer cells. 23,24-dihydrocucurbitacin B exhibited an IC 50 of 40 µM against these two cell lines. The IC 50 value of 23,24-dihydrocucurbitacin B was the same for the two cancer cell lines, however, only the HeLa cancer cell line was used for further experiments. Given these interesting results further studies should focus on evaluation of 23,24-dihydrocucurbitacin B against more cell lines. Although the IC 50 of 23,24-dihydrocucurbitacin B is comparatively higher than that of known anticancer drugs, its low cytotoxicity against normal cervical cells suggests that it may be an effective anticancer molecule. However, 24-synthetic chemistry approaches may be required for the synthesis of more efficient derivatives (13) . Furthermore, 23,24-dihydrocucurbitacin B exhibited low cytotoxicity in normal cells, indicating that it is selective for cancer cells. The results of the current study are consistent with those of previous studies, in which it was determined that 23,24-dihydrocucurbitacin B exhibits anticancer activity against a number of cancer cell types, including prostate and breast cancer cells (13, 14) .
It has also been demonstrated that various anticancer drugs, including cisplatin, Taxon and 5-fluorouracil (12, (15) (16) (17) (18) (19) , exhibit anticancer effects by inducing apoptosis. Furthermore, the resistance of cancer cells to a particular drug is partially due to the resistance of cancer cells to apoptosis (20) . In the current study, DAPI staining was performed to investigate whether 23,24-dihydrocucurbitacin B induces the apoptosis of HeLa cells. The results indicated that 23,24-dihydrocucurbitacin B induces apoptosis in a dose-dependent manner.
In addition, the results of the current study indicated that 23,24-dihydrocucurbitacin B-treated cells exhibited a reduction in the ΔΨm, which was mediated by ROS. These results are consistent with those of a previous study (18) . Thus, the results of the present study indicate that 23,24-dihydrocucurbitacin B may induce apoptosis by increasing intracellular ROS and decreasing the ΔΨm. Several anticancer drugs act against cancer by producing ROS (21, 22) ; for example, afferent A disrupts the ΔΨm and induces oxidative stress, ultimately inducing apoptosis in osteosarcoma cells (23) .
Flow cytometric analysis in the current study indicated that 23,24-dihydrocucurbitacin B induced G 2 /M cell cycle arrest and markedly increased the proportion of HeLa cells in the G 2 phase in a dose-dependent manner. These results are consistent with those of a previous study, which demonstrated that 23,24-dihydrocucurbitacin B induces G 2 /M cell cycle arrest in breast cancer cells (14) . It is hypothesized that the G 2 /M cell cycle arrest of HeLa cells by 23,24-dihydrocucurbitacin B may be due to the regulation of cell cycle-associated proteins.
The PI3K/Akt/mTOR signaling pathway is considered to be an important target for anticancer chemotherapy (24) . Therefore, the effect of 23,24-dihydrocucurbitacin B on the expression of important proteins, including mTOR, p-mTOR, P13K, p-PI3K, Akt and p-Akt, were studied using western blotting. The results indicated that 23,24-dihydrocucurbitacin B-administrated cells exhibited a dose-dependent down regulation of mTOR and p-mTOR proteins. There was also a decrease in the expression of PI3K and p-Akt in HeLa cells treated with 23,24-dihydrocucurbitacin B. The inhibition of the PI3K/AKT/mTOR pathway may be due to a decrease in the expression of mTOR and PI3K or the inhibition of their phosphorylation (25) . However, further studies are required in order to confirm this. The PI3K/AKT/mTOR pathway serves a role in a number of cellular processes, including the proliferation and survival in several cell types and dysregulation of the P13K/AKT pathway is considered to be an important step in the pathogenesis of many diseases, including cancer (25, 26) . Furthermore, dysregulated mTOR stimulation has also been reported to serve a key part in the development of nephropathy and the pathogenesis of HIV-associated malignancies (27) . Therefore, the role of mTOR in the pathogenesis of HIV-associated disorders and cancer suggests that the use of specific P13K/AKT/mTOR inhibitors may be a novel approach to prevent and treat these diseases (27, 28) . 23,24-dihydrocucurbitacin B inhibits this pathway; therefore, it may be effective at preventing the progression of diseases in which mTOR is upregulated. It should be noted that in the current study, the HeLa cell line was the only cell line used in subsequent experiments following preliminary screening of 23,24-dihydrocucurbitacin B against a panel of cervical cancer cell lines. Therefore, further studies focusing on the effect of 23,24-dihydrocucurbitacin B against other cell lines and subsequent in vivo studies are required to provide broader insights into the underlying mechanisms of 23,24-dihydrocucurbitacin B.
In conclusion, the results of the current study indicate that 23,24-dihydrocucurbitacin B may be a potential candidate for the management of cervical cancer by inducing apoptosis, cell cycle arrest and regulating the mTOR/PI3K/Akt signaling pathway. There are limited effective treatments available for cervical cancer; the low toxicity associated with the naturally occurring 23,24-dihydrocucurbitacin B means that it may be developed as a novel treatment for cervical cancer. However, further studies are required to validate its effectiveness in cervical cancer.
